发明名称 |
Use of N-(2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6 dichlorophenyl)pyrido(2,3-d)pyrimidin-7-yl)-N'-(1,1-dimethylethyl)-urea for the preparation of medicament to treat acute myeloid leukemia and chronic myelogenous leukemia |
摘要 |
#CMT# #/CMT# Use of N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6 dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (I) and its hydrates, salts or solvates, for the preparation of medicament to treat leukemia and myeloids leukemia, is claimed. #CMT#ACTIVITY : #/CMT# Cytostatic. The anti-tumor activity of (I) was tested in severe combined immunodeficient mice CB-17. The result showed that (I) exhibited tumor mass reduction of 80%. #CMT#MECHANISM OF ACTION : #/CMT# None given. #CMT#USE : #/CMT# (I) is useful to treat acute myeloid leukemia and chronic myelogenous leukemia (claimed). #CMT#ADVANTAGE : #/CMT# (I) provides an improved treatment for leukemia. #CMT#ADMINISTRATION : #/CMT# Administration of (I) is intravenous or oral (claimed). No dosage details given. |
申请公布号 |
FR2910813(A1) |
申请公布日期 |
2008.07.04 |
申请号 |
FR20060011492 |
申请日期 |
2006.12.28 |
申请人 |
SANOFI AVENTIS SOCIETE ANONYME |
发明人 |
BOURRIE BERNARD;CASELLAS PIERRE |
分类号 |
A61K31/519;A61P35/02 |
主分类号 |
A61K31/519 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|